Medicus Pharma will concentrate SkinJect development on Gorlin syndrome patients with multiple basal cell carcinoma lesions, discontinuing further sporadic BCC development.
This is a summary. For the full story, refer to the original source. Public of India presents verified citizen-relevant reporting.